Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
First targeted therapy may prolong survival of men with advanced prostate cancer.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
In study, test proved able to detect and localize more than 20 types of cancer with a high degree of accuracy.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
A new study and meta-analysis found no long-term benefit from adding radiation therapy soon after surgery.
Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.